John D Diekman - Net Worth and Insider Trading

John D Diekman Net Worth

The estimated net worth of John D Diekman is at least $114 Million dollars as of 2024-04-23. John D Diekman is the Director of IDEAYA Biosciences Inc and owns about 2,963,066 shares of IDEAYA Biosciences Inc (IDYA) stock worth over $111 Million. John D Diekman is the Director of Affymetrix Inc and owns about 138,296 shares of Affymetrix Inc (AFFX) stock worth over $2 Million. John D Diekman is also the Director of Zai Lab Ltd and owns about 67,615 shares of Zai Lab Ltd (ZLAB) stock worth over $1 Million. Details can be seen in John D Diekman's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that John D Diekman has not made any transactions after 2022-02-04 and currently still holds the listed stock(s).

Transaction Summary of John D Diekman

To

John D Diekman Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John D Diekman owns 15 companies in total, including Aprea Therapeutics Inc (APRE) , IDEAYA Biosciences Inc (IDYA) , and Arvinas Inc (ARVN) among others .

Click here to see the complete history of John D Diekman’s form 4 insider trades.

Insider Ownership Summary of John D Diekman

Ticker Comapny Transaction Date Type of Owner
APRE Aprea Therapeutics Inc 2019-10-02 10 percent owner
IDYA IDEAYA Biosciences Inc 2020-11-11 10 percent owner & Former 10% holder
ARVN Arvinas Inc 2018-09-26 10 percent owner
CRNX Crinetics Pharmaceuticals Inc 2018-07-17 10 percent owner
FIXX Homology Medicines Inc 2018-03-27 10 percent owner
SCPH scPharmaceuticals Inc 2017-11-16 10 percent owner
BOLD Audentes Therapeutics Inc 2017-04-24 other: Fomer 10% owner
PZRXQ PhaseRx Inc 2016-05-17 10 percent owner
VIVE Viveve Medical Inc 2014-09-23 10 percent owner
CDTX Cidara Therapeutics Inc 2015-04-14 10 percent owner
EPRSQ EPIRUS Biopharmaceuticals Inc 2015-02-04 10 percent owner
AFFX Affymetrix Inc 2012-05-11 director
ZLAB Zai Lab Ltd 2022-02-04 director
PEARQ Pear Therapeutics Inc 2021-12-03 10 percent owner
SKYE Skye Bioscience Inc 2023-08-18 10 percent owner

John D Diekman Latest Holdings Summary

John D Diekman currently owns a total of 3 stocks. Among these stocks, John D Diekman owns 2,963,066 shares of IDEAYA Biosciences Inc (IDYA) as of May 28, 2019, with a value of $111 Million and a weighting of 97.42%. John D Diekman owns 138,296 shares of Affymetrix Inc (AFFX) as of June 30, 2011, with a value of $2 Million and a weighting of 1.69%. John D Diekman also owns 67,615 shares of Zai Lab Ltd (ZLAB) as of February 4, 2022, with a value of $1 Million and a weighting of 0.89%.

Latest Holdings of John D Diekman

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
IDYA IDEAYA Biosciences Inc 2019-05-28 2,963,066 37.59 111,381,651
AFFX Affymetrix Inc 2011-06-30 138,296 14.01 1,937,527
ZLAB Zai Lab Ltd 2022-02-04 67,615 14.99 1,013,549

Holding Weightings of John D Diekman


John D Diekman Form 4 Trading Tracker

According to the SEC Form 4 filings, John D Diekman has made a total of 1 transactions in IDEAYA Biosciences Inc (IDYA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in IDEAYA Biosciences Inc is the acquisition of 250,000 shares on May 28, 2019, which cost John D Diekman around $3 Million.

According to the SEC Form 4 filings, John D Diekman has made a total of 0 transactions in Affymetrix Inc (AFFX) over the past 5 years. The most-recent trade in Affymetrix Inc is the sale of 10,000 shares on June 30, 2011, which brought John D Diekman around $80,000.

According to the SEC Form 4 filings, John D Diekman has made a total of 4 transactions in Zai Lab Ltd (ZLAB) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Zai Lab Ltd is the sale of 1,000 shares on February 4, 2022, which brought John D Diekman around $50,170.

Insider Trading History of John D Diekman

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

John D Diekman Trading Performance

GuruFocus tracks the stock performance after each of John D Diekman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John D Diekman is -46.8%. GuruFocus also compares John D Diekman's trading performance to market benchmark return within the same time period. The performance of stocks bought by John D Diekman within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how John D Diekman's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of John D Diekman

Average Return

Outperforming Transactions

Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -12.55 -46.8 -34.5 -17.43 32.96 -1.76
Relative Return to S&P 500(%) -17.52 -49.85 -47.03 -25.52 10.51 -15.82

John D Diekman Ownership Network

Ownership Network List of John D Diekman

No Data

Ownership Network Relation of John D Diekman


John D Diekman Owned Company Details

What does Aprea Therapeutics Inc do?

Who are the key executives at Aprea Therapeutics Inc?

John D Diekman is the 10 percent owner of Aprea Therapeutics Inc. Other key executives at Aprea Therapeutics Inc include President & CEO Oren Gilad , SrVP/CFO/Prin. Fin &Acctg. Off John P. Hamill , and director & President & CEO Christian S Schade .

Aprea Therapeutics Inc (APRE) Insider Trades Summary

Over the past 18 months, John D Diekman made no insider transaction in Aprea Therapeutics Inc (APRE). Other recent insider transactions involving Aprea Therapeutics Inc (APRE) include a net purchase of 16,957 shares made by Bernd R. Seizinger , a net purchase of 6,860 shares made by Henneman John B Iii , and a net purchase of 2,000 shares made by Oren Gilad .

In summary, during the past 3 months, insiders sold 0 shares of Aprea Therapeutics Inc (APRE) in total and bought 16,730 shares, with a net purchase of 16,730 shares. During the past 18 months, 0 shares of Aprea Therapeutics Inc (APRE) were sold and 26,827 shares were bought by its insiders, resulting in a net purchase of 26,827 shares.

Aprea Therapeutics Inc (APRE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aprea Therapeutics Inc Insider Transactions

No Available Data

John D Diekman Mailing Address

Above is the net worth, insider trading, and ownership report for John D Diekman. You might contact John D Diekman via mailing address: C/o 5 Am Ventures, 501 2nd Street, Suite 350, San Francisco Ca 94107.

Discussions on John D Diekman

No discussions yet.